SCHEMBL5465339

SCHEMBL5465339

COc1ccccc1N1CCC(C#N)(c2ccccc2OC)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.55
DRD3 P35462 6/20 0.55
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
ADRB1 P08588 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTR3A P46098 1/20 0.50
HTR6 P50406 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
LMNA P02545 2/20 0.49
MAPT P10636 2/20 0.49
DRD4 P21917 2/20 0.46
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
KDM4E B2RXH2 3/20 0.45
HTT P42858 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470879 0.87 DRD2 (0.48) DRD2DRD3HTR3EHTR3BADRB1
SCHEMBL4882594 0.86 DRD2 (0.55) DRD2DRD3HTR3EHTR3BADRB1
SCHEMBL6816695 0.84 KMT2A (0.55) DRD2DRD3ADRA1DADRA1AADRA1B
SCHEMBL2048048 0.83 SIGMAR1 (0.47) SIGMAR1MAPTADRA1DADRA1AADRA1B
SCHEMBL5465370 0.83 DRD2 (0.51) DRD2DRD3HTR3EHTR3BADRB1
SCHEMBL5476121 0.82 KMT2A (0.53) DRD2DRD3HTR3EHTR3BADRB1
SCHEMBL5478188 0.82 MAPT (0.51) DRD2DRD3HTR3EHTR3BADRB1
SCHEMBL5465331 0.81 ALDH1A1 (0.52) DRD2DRD3HTR3EHTR3BADRB1
SCHEMBL18324410 0.81 ADRA1D (0.53) ADRA1DADRA1AADRA1BKMT2A
SCHEMBL451300 0.81 SIGMAR1 (0.45) SIGMAR1MAPTADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078120-A1 Novel piperidine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-05 US disclosed
EP-1679069-A1 NOVEL PIPERIDINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078120-A1 Novel piperidine derivative LDLR, PRMT5, MSR1 DRD2 551/4885DRD3 552/4885HTR3E 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.